[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2): 69-90. [2] Mayne ST, Cartmel B, Kirsh V, et al. Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx [J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(12): 3368-3374. [3] Petersen PE. Oral cancer prevention and control-the approach of the World Health Organization [J]. Oral Oncol, 2009, 45(4-5): 454-460. [4] Tanaka T, Tanaka M. Oral carcinogenesis and oral cancer chemoprevention: a review [J]. Patholog Res Int, 2011, 2011: 431246. [5] Shiu MN, Chen TH. Impact of betel quid, tobacco and alcohol on three-stage disease natural history of oral leukoplakia and cancer: implication for prevention of oral cancer [J]. Eur J Cancer Prev, 2004, 13(1): 39-45. [6] Shaw R. The epigenetics of oral cancer [J]. Int J Oral Maxillofac Surg, 2006, 35(2): 101-108. [7] Ruwali M, Singh M, Pant MC, et al. Polymorphism in glutathione S-transferases: susceptibility and treatment outcome for head and neck cancer [J]. Xenobiotica, 2011, 41(12): 1122-1130. [8] Karen-Ng LP, Marhazlinda J, Rahman ZA, et al. Combined effects of isothiocyanate intake, glutathione S-transferase polymorphisms and risk habits for age of oral squamous cell carcinoma development[J]. Asian Pac J Cancer Prev, 2011, 12(5): 1161-1166. [9] Chen MK, Tsai HT, Chung TT, et al. Glutathione S-transferase P1 and alpha gene variants; role in susceptibility and tumor size development of oral cancer [J]. Head Neck, 2010, 32(8): 1079-1087. [10] Duarte EC, Ribeiro DC, Gomez MV, et al. Genetic polymorphisms of carcinogen metabolizing enzymes are associated with oral leukoplakia development and p53 overexpression [J]. Anticancer Res, 2008, 28(2A): 1101-1106. [11] Sikdar N, Paul RR and Roy B. Glutathione S-transferase M3 (A/A) genotype as a risk factor for oral cancer and leukoplakia among Indian tobacco smokers [J]. Int J Cancer, 2004, 109(1): 95-101. [12] Park JY, Schantz SP, Stern JC, et al. Association between glutathione S-transferase pi genetic polymorphisms and oral cancer risk [J]. Pharmacogenetics, 1999, 9(4): 497-504. [13] Katoh T, Kaneko S, Takasawa S, et al. Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer [J]. Pharmacogenetics, 1999, 9(2): 165-169. [14] Jourenkova-Mironova N, Voho A, Bouchardy C, et al. Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers [J]. Int J Cancer, 1999, 81(1): 44-48. [15] Matthias C, Bockmühl U, Jahnke V, et al. The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas [J]. Pharmacogenetics, 1998, 8(1): 1-6. [16] Yadav DS, Devi TR, Ihsan R, et al. Polymorphisms of glutathione-S-transferase genes and the risk of aerodigestive tract cancers in the Northeast Indian population [J]. Genet Test Mol Biomarkers, 2010, 14(5): 715-723. [17] Mahimkar MB, Samant TA, Kannan S, et al. Influence of genetic polymorphisms on frequency of micronucleated buccal epithelial cells in leukoplakia patients[J]. Oral Oncol,2010,46(10):761-766. [18] Hatagima A, Costa EC, Marques CF, et al. Glutathione S-transferase polymorphisms and oral cancer: a case-control study in Rio de Janeiro, Brazil [J]. Oral Oncol, 2008, 44(2): 200-207. [19] Peters ES, McClean MD, Marsit CJ, et al. Glutathione S-transferase polymorphisms and the synergy of alcohol and tobacco in oral, pharyngeal, and laryngeal carcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(11): 2196-2202. [20] Amador AG, Righi PD, Radpour S, et al. Polymorphisms of xenobiotic metabolizing genes in oropharyngeal carcinoma [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2002, 93(4): 440-445. [21] da Costa BR, Cevallos M, Altman DG, et al. Uses and misuses of the STROBE statement: bibliographic study [J]. BMJ Open, 2011, 1(1): e000048. [22] Jackson D, Baker R, Bowden J. A sensitivity analysis framework for the treatment effect measure used in the meta-analysis of comparative binary data from randomised controlled trials [J]. Stat Med, 2013, 32(6): 931-940. [23] Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis[J]. JAMA,2006,295(6): 676-680. [24] Zintzaras E, Chatzoulis DZ, Karabatsas CH, et al. The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis [J]. J Hum Genet, 2005, 50(6): 267-275. [25] Lee SA, Fowke JH, Lu W, et al. Cruciferous vegetables, the GSTP1 Ile105Val genetic polymorphism, and breast cancer risk [J]. Am J Clin Nutr, 2008, 87(3): 753-760. [26] Rybicki BA, Neslund-Dudas C, Nock NL, et al. Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism [J]. Cancer Detect Prev, 2006, 30(5): 412-422. [27] Sun N, Sun X, Chen B, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer [J]. Cancer Chemother Pharmacol, 2010, 65(3): 437-446. |